Fortrea sells pair of businesses to private equity firm to become 'pure-play' CRO AI is already widely used in drug development and is advancing into clinical trials, too, as evidenced by the many ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) in Q1 CY2025, but sales fell by 1.6% year on year to $651.3 million. The company’s full-year revenue guidance of $2.5 billion at the midpoint ...

However, the nuts and bolts of clinical trials are rooted in quite traditional methods and processes. Fortrea aims to modernize the way clinical trials are run with innovation that combines the ...

Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies. Fortrea has extensive experience ...

There are a number of sources of information on clinical trials, most of which are designed for patients. One of the best places to start is ClinicalTrials.gov, which is run by the National ...

Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies. Fortrea has extensive experience ...

Fortrea, a recent Labcorp spin-off ... According to this March 2024 article by PharmaExec.com, new clinical trials were down 15% in 2023 from 2022 and down 21% in 2023 from 2021 The article ...

Spun off from Labcorp in 2023, Fortrea Holdings (NASDAQ:FTRE) provides contract research and development services for pharmaceutical and biotechnology companies, specializing in clinical trials ...

The growth is driven by pharma and biotech companies outsourcing clinical trials to specialized providers. Since late-stage trials are larger and more complex, they are more frequently outsourced ...

However, the nuts and bolts of clinical trials are rooted in quite traditional methods and processes. Fortrea aims to modernize the way clinical trials are run with innovation that combines the ...